UROGEN PHARMA LTD (URGN:NASDAQ)
$26.66 -1.47 (-5.2257%)
Analysed UROGEN PHARMA LTD (URGN:NASDAQ) News Sources
UroGen (URGN) Q1 2026 Earnings Transcript
07-05-2026
fool.com
Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum
09-05-2026
yahoo.com
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
11-05-2026
yahoo.com
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
13-05-2026
yahoo.com
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
15-05-2026
yahoo.com
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
19-05-2026
yahoo.com
Sector Update: Healthcare Stocks Gain Late Afternoon
19-05-2026
yahoo.com
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
21-05-2026
yahoo.com
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
23-05-2026
fool.com
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
23-05-2026
fool.com
What is the current price of UROGEN PHARMA LTD (URGN:NASDAQ)?
The current price of UROGEN PHARMA LTD (URGN:NASDAQ) is $26.66.
UROGEN PHARMA LTD (URGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of UROGEN PHARMA LTD (URGN:NASDAQ) since the previous trading day is $-1.47.
UROGEN PHARMA LTD (URGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of UROGEN PHARMA LTD (URGN:NASDAQ) since the previous trading day is -5.2257%.
What is the most recent average sentiment score for UROGEN PHARMA LTD (URGN:NASDAQ)?
The most recent average sentiment score for UROGEN PHARMA LTD (URGN:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for UROGEN PHARMA LTD (URGN:NASDAQ)?
The most recent sentiment for UROGEN PHARMA LTD (URGN:NASDAQ) is .
SEC-8K** Filing Available For UROGEN PHARMA LTD (URGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.